Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kova vs Metabolyz

Kova
Graded #498

Lower grade

vs+15.300000000000004
Metabolyz
Graded #339

Higher grade

The verdict

Metabolyz takes it — 59.6/100 to 44.3/100.

Metabolyz grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Metabolyz is a nationwide GLP-1 telehealth platform offering three compounded programs — standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for patients near goal weight or intolerant…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMetabolyz +25
20
45
Dose & formulationEven
40
40
Clinical oversightMetabolyz +10
71
81
Labs & monitoringMetabolyz +11
52
63
FulfillmentMetabolyz +25
61
86
Contract termsMetabolyz +30
25
55
Kova · left barMetabolyz · right bar

The numbers

MetricKovaMetabolyz
WeighScore44.3/10059.6/100
GradeCC
Scorecard rank#498#339
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Kova

Graded #498 · C

Strengths

  • Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
  • Medication is included in the plan price, with no separate pharmacy charge
  • States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
  • Companion app tracks weight, protein and side effects, with medication schedule reminders
  • You are not charged unless a provider approves treatment

Where it loses points

  • At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
  • The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
  • Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
  • Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
  • No pharmacy or prescribing medical group is named anywhere on the site
Metabolyz

Graded #339 · C

Strengths

  • Three GLP-1 programs: standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for near-goal or dose-sensitive patients
  • Nutrition, movement, and lifestyle coaching included in all programs at no extra charge
  • Medication compounded in licensed 503A/503B US pharmacies with temperature-controlled, unmarked direct-to-door delivery
  • Licensed provider supervision with direct messaging access and structured check-ins throughout
  • Telehealth across all 50 states; BMI 27+ eligibility (25+ with weight-related condition)

Where it loses points

  • Pricing is fully gated — not disclosed until after consultation, preventing upfront cost comparison
  • Compounded GLP-1 only — no brand-name options (Wegovy, Zepbound) available
  • No LegitScript certification or named medical leadership found on public-facing pages
  • Labs not mentioned as included — unclear whether baseline or follow-up bloodwork is offered
  • Newer brand with no external reviews, published outcomes data, or notable accreditations

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard